Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease

Human Immunology Bioscience aims to stand apart in autoimmune disease drug research with therapies that address cells at the root of a range of allergic and inflammatory disorders. The biotech has a lead program licensed from MorphoSys in clinical development for two rare kidney diseases and $120 million to support that antibody and other biologic drugs in its pipeline.